Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07805967
Recruiting Observational

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

NCT07805967 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Soochow University
Phase
Observational
Started
2025-11-12
Last updated
2026-09-08

Condition(s) studied

Multiple System AtrophyDementia With Lewy Bodies (DLB)Progressive Supranuclear Palsy (PSP)Corticobasal Degeneration (CBD)

Investigational drug(s) / intervention(s)

We did not apply any interventions; only observational research was conducted.

We did not apply any interventions; only observational research was conducted.: We did not apply any interventions; only observational research was conducted.

Study summary

This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) . 2. DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) . 3. PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years . 4. CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb). Exclusion Criteria: 1. Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure . 2. Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .

Primary outcome measure(s)

  • Natural disease progression of various atypical parkinsonian syndromes — up to 36 months
    To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.

Trial sites (20)

FacilityCityRegionStatus
Changshu Hospital Affiliated to Nanjing University of Chinese Medicine Changshu Jiangsu Recruiting
The second People's Hospital of Huai'an Huai'an Jiangsu Not Yet Recruiting
The First People's Hospial of Kunshan Kunshan Jiangsu Not Yet Recruiting
Jiangsu Province Official Hospital Nanjing Jiangsu Not Yet Recruiting
The Second Affiliated Hospital of Nantong University Nantong Jiangsu Not Yet Recruiting
Jiangsu Province (Suqian) Hospital Suqian Jiangsu Recruiting
The Forth Affiliated Hospital of Soochow University Suzhou Jiangsu Recruiting
The Second Affiliated Hospital of Soochow University Suzhou Jiangsu Recruiting
The Second Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu Not Yet Recruiting
Yancheng Third People's Hospital Yancheng Jiangsu Recruiting
Affiliated Hospital of Yangzhou University Yangzhou Jiangsu Not Yet Recruiting
Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine/Zhangjiagang Traditional Chinese Medicine Hospital Zhangjiagang Jiangsu Not Yet Recruiting
The Forth People's Hospital of Zhenjiang Zhenjiang Jiangsu Recruiting
Yantai Yuhuangding Hospital Yantai Shandong Not Yet Recruiting
Mianyang 404 Hospital Mianyang Sichuan Not Yet Recruiting
Jiaxing Second Hospital Jiaxing Zhejiang Not Yet Recruiting
Deyang People's Hospital Deyang China Not Yet Recruiting
Changxing people' s hospital Huzhou China Not Yet Recruiting
Affiliated Hospital of Nantong University Nantong China Not Yet Recruiting
The Affiliated Hospital of Xuzhou Medical University Xuzhou China Not Yet Recruiting

More Second Affiliated Hospital of Soochow University trials in China

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC Recruiting
DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes Starting soon
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors Recruiting
Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor Recruiting
Light Therapy in Parkinson's Disease Recruiting

Other trials for the same condition

Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy Starting soon
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy Recruiting
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases Starting soon
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers Recruiting
AI-Enhanced Optimization of Acute Levodopa Challenge Test Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07805967 on ClinicalTrials.gov ↗ ← All trials in China